Inqovi
Near Add Your Location
Accepting patients
ASTX727, Venetoclax, and Gilteritinib
A Phase I/II Study of ASTX727, Venetoclax, and Gilteritinib for Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome With an Activating FLT3 Mutation
- BCL-2 Inhibitor
- Cytidine Deaminase Inhibitor
- Nucleoside Metabolic Inhibitor
- Tyrosine Kinase (TK) Inhibitor
- Phase 1/2
Accepting patients
DEC-C Post-Transplant
A Phase I/II Trial of Pre-emptive Therapy With DEC-C to Improve Outcomes in MDS Patients With Measurable Residual Disease Post Allogeneic Hematopoietic Cell Transplant
- Cytidine Deaminase Inhibitor
- Phase 1/2
Accepting patients
Venetoclax in Combination With ASTX727
Venetoclax in Combination With ASTX727, an All-Oral Therapy for Chronic Myelomonocytic Leukemia and Other MDS/MPN With Excess Blasts (VICTORY-MDS/MPN): A Randomized, Phase 2 Trial
- BCL-2 Inhibitor
- Hypomethylating Agents (HMA)
- Phase 2
Accepting patients
Venetoclax in Pre- and Post-Transplant Therapy
A Phase 1 Study of Adding Venetoclax to a Reduced Intensity Conditioning Regimen and to Maintenance in Combination With a Hypomethylating Agent After Allogeneic Hematopoietic Cell Transplantation for Patients With High Risk AML, MDS, and MDS/MPN Overlap Syndromes
- Allogeneic Stem Cell Transplant
- Antimetabolites
- BCL-2 Inhibitor
- Chemotherapy
- Hypomethylating Agents (HMA)
- Phase 1
Accepting patients
ABNL-MARRO
The ABNL-MARRO 001 Study: A Phase 1/2 Study of Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes.
- Chemotherapy
- Phase 1/2
- Has results
Showing 1-5 of 5